Randomized controlled trial: Roxatidine vs omeprazole for non-erosive reflux disease

Kazuhiko Nakamura, Hirotada Akiho, Toshiaki Ochiai, Yasuaki Motomura, Naomi Higuchi, Risa Okamoto, Noriaki Matsui, Daisuke Yasuda, Kazuya Akahoshi, Teppei Kabemura, Eikichi Ihara, Naohiko Harada, Tetsuhide Ito, Ryoichi Takayanagi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: Proton pump inhibitor (PPI) therapy is considered as the first choice for treatment of non-erosive reflux disease (NERD). However, NERD is less sensitive to PPIs than erosive gastroesophageal reflux disease (GERD) and the differences between PPIs and H2 receptor antagonists are less evident in NERD than in erosive GERD. Since gastric acid secretion is lower in the Japanese population than in Western populations, we aimed to investigate whether PPI therapy is really necessary for NERD patients in Japan. Methodology: Thirty-three symptomatic endoscopically diagnosed NERD patients were randomly assigned to receive roxatidine acetate 75 mg twice daily (n=16) or omeprazole 20 mg once daily (n=17). Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale at baseline and after 4 and 8 weeks of treatment. Results: Both roxatidine and omeprazole significantly improved the heartburn score at 4 and 8 weeks. The clinical response rates did not differ between roxatidine and omeprazole. Both roxatidine and omeprazole significantly relieved not only reflux but also abdominal pain and indigestion. The degrees of improvement did not differ between the two groups. Conclusion: Roxatidine relieved the symptoms of NERD patients with similar effectiveness to omeprazole. Therefore, roxatidine may be a good choice for NERD treatment.

Original languageEnglish
Pages (from-to)497-500
Number of pages4
JournalHepato-gastroenterology
Volume57
Issue number99-100
Publication statusPublished - May 1 2010

Fingerprint

Omeprazole
Randomized Controlled Trials
Proton Pump Inhibitors
Gastroesophageal Reflux
Therapeutics
Heartburn
Histamine H2 Receptors
Dyspepsia
Gastric Acid
roxatidine acetate
Abdominal Pain
Population
Japan

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Nakamura, K., Akiho, H., Ochiai, T., Motomura, Y., Higuchi, N., Okamoto, R., ... Takayanagi, R. (2010). Randomized controlled trial: Roxatidine vs omeprazole for non-erosive reflux disease. Hepato-gastroenterology, 57(99-100), 497-500.

Randomized controlled trial : Roxatidine vs omeprazole for non-erosive reflux disease. / Nakamura, Kazuhiko; Akiho, Hirotada; Ochiai, Toshiaki; Motomura, Yasuaki; Higuchi, Naomi; Okamoto, Risa; Matsui, Noriaki; Yasuda, Daisuke; Akahoshi, Kazuya; Kabemura, Teppei; Ihara, Eikichi; Harada, Naohiko; Ito, Tetsuhide; Takayanagi, Ryoichi.

In: Hepato-gastroenterology, Vol. 57, No. 99-100, 01.05.2010, p. 497-500.

Research output: Contribution to journalArticle

Nakamura, K, Akiho, H, Ochiai, T, Motomura, Y, Higuchi, N, Okamoto, R, Matsui, N, Yasuda, D, Akahoshi, K, Kabemura, T, Ihara, E, Harada, N, Ito, T & Takayanagi, R 2010, 'Randomized controlled trial: Roxatidine vs omeprazole for non-erosive reflux disease', Hepato-gastroenterology, vol. 57, no. 99-100, pp. 497-500.
Nakamura K, Akiho H, Ochiai T, Motomura Y, Higuchi N, Okamoto R et al. Randomized controlled trial: Roxatidine vs omeprazole for non-erosive reflux disease. Hepato-gastroenterology. 2010 May 1;57(99-100):497-500.
Nakamura, Kazuhiko ; Akiho, Hirotada ; Ochiai, Toshiaki ; Motomura, Yasuaki ; Higuchi, Naomi ; Okamoto, Risa ; Matsui, Noriaki ; Yasuda, Daisuke ; Akahoshi, Kazuya ; Kabemura, Teppei ; Ihara, Eikichi ; Harada, Naohiko ; Ito, Tetsuhide ; Takayanagi, Ryoichi. / Randomized controlled trial : Roxatidine vs omeprazole for non-erosive reflux disease. In: Hepato-gastroenterology. 2010 ; Vol. 57, No. 99-100. pp. 497-500.
@article{045160f50b1c4124bb12b4714d4be6a7,
title = "Randomized controlled trial: Roxatidine vs omeprazole for non-erosive reflux disease",
abstract = "Background/Aims: Proton pump inhibitor (PPI) therapy is considered as the first choice for treatment of non-erosive reflux disease (NERD). However, NERD is less sensitive to PPIs than erosive gastroesophageal reflux disease (GERD) and the differences between PPIs and H2 receptor antagonists are less evident in NERD than in erosive GERD. Since gastric acid secretion is lower in the Japanese population than in Western populations, we aimed to investigate whether PPI therapy is really necessary for NERD patients in Japan. Methodology: Thirty-three symptomatic endoscopically diagnosed NERD patients were randomly assigned to receive roxatidine acetate 75 mg twice daily (n=16) or omeprazole 20 mg once daily (n=17). Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale at baseline and after 4 and 8 weeks of treatment. Results: Both roxatidine and omeprazole significantly improved the heartburn score at 4 and 8 weeks. The clinical response rates did not differ between roxatidine and omeprazole. Both roxatidine and omeprazole significantly relieved not only reflux but also abdominal pain and indigestion. The degrees of improvement did not differ between the two groups. Conclusion: Roxatidine relieved the symptoms of NERD patients with similar effectiveness to omeprazole. Therefore, roxatidine may be a good choice for NERD treatment.",
author = "Kazuhiko Nakamura and Hirotada Akiho and Toshiaki Ochiai and Yasuaki Motomura and Naomi Higuchi and Risa Okamoto and Noriaki Matsui and Daisuke Yasuda and Kazuya Akahoshi and Teppei Kabemura and Eikichi Ihara and Naohiko Harada and Tetsuhide Ito and Ryoichi Takayanagi",
year = "2010",
month = "5",
day = "1",
language = "English",
volume = "57",
pages = "497--500",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "99-100",

}

TY - JOUR

T1 - Randomized controlled trial

T2 - Roxatidine vs omeprazole for non-erosive reflux disease

AU - Nakamura, Kazuhiko

AU - Akiho, Hirotada

AU - Ochiai, Toshiaki

AU - Motomura, Yasuaki

AU - Higuchi, Naomi

AU - Okamoto, Risa

AU - Matsui, Noriaki

AU - Yasuda, Daisuke

AU - Akahoshi, Kazuya

AU - Kabemura, Teppei

AU - Ihara, Eikichi

AU - Harada, Naohiko

AU - Ito, Tetsuhide

AU - Takayanagi, Ryoichi

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Background/Aims: Proton pump inhibitor (PPI) therapy is considered as the first choice for treatment of non-erosive reflux disease (NERD). However, NERD is less sensitive to PPIs than erosive gastroesophageal reflux disease (GERD) and the differences between PPIs and H2 receptor antagonists are less evident in NERD than in erosive GERD. Since gastric acid secretion is lower in the Japanese population than in Western populations, we aimed to investigate whether PPI therapy is really necessary for NERD patients in Japan. Methodology: Thirty-three symptomatic endoscopically diagnosed NERD patients were randomly assigned to receive roxatidine acetate 75 mg twice daily (n=16) or omeprazole 20 mg once daily (n=17). Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale at baseline and after 4 and 8 weeks of treatment. Results: Both roxatidine and omeprazole significantly improved the heartburn score at 4 and 8 weeks. The clinical response rates did not differ between roxatidine and omeprazole. Both roxatidine and omeprazole significantly relieved not only reflux but also abdominal pain and indigestion. The degrees of improvement did not differ between the two groups. Conclusion: Roxatidine relieved the symptoms of NERD patients with similar effectiveness to omeprazole. Therefore, roxatidine may be a good choice for NERD treatment.

AB - Background/Aims: Proton pump inhibitor (PPI) therapy is considered as the first choice for treatment of non-erosive reflux disease (NERD). However, NERD is less sensitive to PPIs than erosive gastroesophageal reflux disease (GERD) and the differences between PPIs and H2 receptor antagonists are less evident in NERD than in erosive GERD. Since gastric acid secretion is lower in the Japanese population than in Western populations, we aimed to investigate whether PPI therapy is really necessary for NERD patients in Japan. Methodology: Thirty-three symptomatic endoscopically diagnosed NERD patients were randomly assigned to receive roxatidine acetate 75 mg twice daily (n=16) or omeprazole 20 mg once daily (n=17). Gastrointestinal symptoms were assessed using the Gastrointestinal Symptom Rating Scale at baseline and after 4 and 8 weeks of treatment. Results: Both roxatidine and omeprazole significantly improved the heartburn score at 4 and 8 weeks. The clinical response rates did not differ between roxatidine and omeprazole. Both roxatidine and omeprazole significantly relieved not only reflux but also abdominal pain and indigestion. The degrees of improvement did not differ between the two groups. Conclusion: Roxatidine relieved the symptoms of NERD patients with similar effectiveness to omeprazole. Therefore, roxatidine may be a good choice for NERD treatment.

UR - http://www.scopus.com/inward/record.url?scp=77955474942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955474942&partnerID=8YFLogxK

M3 - Article

C2 - 20698216

AN - SCOPUS:77955474942

VL - 57

SP - 497

EP - 500

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 99-100

ER -